VCT220 oral GLP-1: what its 16-week Phase II obesity trial found

What the source reports

A randomized Phase II trial published in Signal Transduction and Targeted Therapy tested VCT220, an experimental once-daily oral GLP-1 receptor agonist, in adults with obesity or overweight and at least one related condition. Unlike peptide medicines such as semaglutide, VCT220 is a nonpeptide small molecule.

After 16 weeks, model-estimated average body-weight reduction ranged from 5.75% with 80 mg to 9.73% with the fastest-titrated 160 mg regimen. The pooled placebo groups had an estimated average reduction of 1.61%.

All four VCT220 regimens produced statistically greater average weight reduction than placebo. This is a positive dose-finding result, but VCT220 remains investigational and the trial was too short to establish durable weight control, long-term safety or an advantage over an approved medicine.

How the Phase II trial worked

The multicentre, double-blind trial enrolled 250 adults across 13 sites in China. Within dose cohorts, participants were randomly assigned in a three-to-one ratio to VCT220 or matching placebo, alongside standardized lifestyle counselling.

The study tested target doses of 80 mg, 120 mg and 160 mg. The highest-dose cohort was divided between faster and slower titration schedules, allowing researchers to explore whether the pace of dose escalation changed effectiveness or tolerability.

Participants were aged 18 to 75 and did not have type 1 or type 2 diabetes. The average age was 32.4 years, average starting body weight was 91.76 kg and average BMI was 32.03; 58.4% were men and 41.6% were women.

The weight results by dose

At week 16, estimated average weight change was −5.75% with 80 mg, −7.42% with 120 mg, −9.40% with 160 mg using slower titration and −9.73% with 160 mg using faster titration. The corresponding estimate for pooled placebo was −1.61%.

The estimated placebo-adjusted differences ranged from −4.14 percentage points at 80 mg to −8.11 percentage points with fast-titrated 160 mg. The primary analysis used multiple imputation to account for missing measurements, and sensitivity analyses were reported as consistent with the main result.

The curves had not visibly plateaued by week 16, but that does not establish that weight reduction would continue at the same pace. A short trend cannot reliably predict the result at one year or beyond.

How many participants crossed the 5% threshold?

At least 5% weight reduction was estimated in 55.4% of participants receiving 80 mg, 72.6% receiving 120 mg, 77.4% receiving fast-titrated 160 mg and 90.3% receiving slow-titrated 160 mg. The placebo estimate was 13.1%.

For the 10% threshold, response ranged from 4.6% at 80 mg to 45.2% with fast-titrated 160 mg, compared with 1.6% for placebo. Few participants reached 15%, and only one participant in the fast-titration group reached at least 20%.

Threshold results can be useful for describing a study population, but they do not predict an individual's response. They also should not be compared directly with percentages from longer trials of different medicines.

Fast and slow titration told different stories

The two 160 mg schedules produced similar average weight reductions: 9.40% with slower titration and 9.73% with faster titration. Their gastrointestinal-event rates were less similar.

Gastrointestinal adverse events occurred in 80.6% of participants in the fast-titration group and 64.5% in the slow-titration group, compared with 27.9% in pooled placebo. The trial therefore suggests that reaching the target more gradually may improve short-term tolerability without an obvious loss of average weight effect by week 16.

That comparison was exploratory and involved only about 31 participants in each active 160 mg subgroup. It cannot define a clinical dosing schedule, and any future regimen would need confirmation in larger trials and regulatory review.

Gastrointestinal effects were common

Across the VCT220 groups, gastrointestinal events increased with dose and were most frequent during escalation. Nausea ranged from 41.5% at 80 mg to 58.1% with fast-titrated 160 mg, compared with 8.2% for placebo.

Vomiting ranged from 13.8% to 41.9% across VCT220 regimens and diarrhoea from 17.7% to 29.0%, while both were reported in 8.2% of placebo participants. Most gastrointestinal events were graded mild or moderate, and two participants receiving VCT220 permanently discontinued because of them.

Four participants stopped assigned treatment because of any adverse event: one in the 80 mg group, one in the 120 mg group, one in the fast-titration 160 mg group and one receiving placebo. No deaths or drug-related serious adverse events were reported.

The metabolic findings were exploratory

The study also reported changes in waist circumference, blood pressure, HbA1c, fasting insulin, total cholesterol and triglycerides. These measures generally moved in a favourable direction with VCT220, with larger changes often seen at higher doses.

Those outcomes were not arranged in a prespecified statistical hierarchy capable of controlling the overall risk of false-positive findings across many comparisons. The authors described them as exploratory and said they require confirmation in Phase III evaluation.

Changes in risk markers are not evidence that a medicine prevents heart attacks, strokes, diabetes or death. Clinical-outcome trials would be needed to test those questions.

Why an oral small molecule matters

VCT220 is designed to activate the GLP-1 receptor without being a peptide. The paper reports that it does not use the absorption-enhancing delivery system required by oral semaglutide and was taken without the same fasting administration restriction in this trial.

A tablet may change manufacturing, storage and daily routines, but oral administration does not make a medicine automatically safer, easier to tolerate or more effective. It also does not establish that people will remain on treatment longer in routine care.

Several oral small-molecule GLP-1 candidates are in development. VCT220's result adds to that research field; it does not establish a ranking against aleniglipron, orforglipron, oral semaglutide or injectable treatments.

Population, analysis and sponsor limitations

All sites were in China, the population was relatively young on average and people with significant conditions such as advanced heart failure or severe renal dysfunction were excluded. Responses and tolerability may differ in older, more medically complex or more ethnically diverse populations.

The study pooled placebo participants from several dose cohorts with different escalation schedules. The authors acknowledged possible bias from pooled placebo groups, site effects and differing titration cadence, although the randomized and blinded design remains an important strength.

Chengdu Vincentage Pharma, the developer of VCT220, funded the study. Two authors were full-time company employees, one of whom reported company stock ownership, and employees contributed to study design and data interpretation.

What remains uncertain

The study does not show whether weight reduction persists through a year or longer, where a plateau might occur, what happens after stopping, or whether uncommon adverse effects emerge with greater exposure.

It is also unknown whether VCT220 will work similarly in global populations, whether the metabolic-marker changes translate into better health outcomes, and how it would compare directly with an approved oral or injectable treatment.

Larger and longer Phase III trials with broader populations, prespecified safety analyses and appropriate active comparisons will be needed before regulators can assess whether VCT220 has a clinical role.

Bottom line

In a 250-person Phase II trial, experimental once-daily VCT220 produced dose-related average weight reduction over 16 weeks, reaching 9.73% with the fast-titrated 160 mg regimen compared with 1.61% for pooled placebo.

The strongest takeaway is proof of concept for another oral small-molecule GLP-1 candidate. The equally important caution is that gastrointestinal effects were common, the trial was short and geographically narrow, and VCT220 is not an approved treatment.